2052 related articles for article (PubMed ID: 8784367)
1. Bone marrow transplantation from genetically HLA-nonidentical donors in children with fatal inherited disorders excluding severe combined immunodeficiencies: use of two monoclonal antibodies to prevent graft rejection.
Jabado N; Le Deist F; Cant A; De Graeff-Meeders ER; Fasth A; Morgan G; Vellodi A; Hale G; Bujan W; Thomas C; Cavazzana-Calvo M; Wijdenes J; Fischer A
Pediatrics; 1996 Sep; 98(3 Pt 1):420-8. PubMed ID: 8784367
[TBL] [Abstract][Full Text] [Related]
2. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
[TBL] [Abstract][Full Text] [Related]
3. Reduction of graft failure by a monoclonal antibody (anti-LFA-1 CD11a) after HLA nonidentical bone marrow transplantation in children with immunodeficiencies, osteopetrosis, and Fanconi's anemia: a European Group for Immunodeficiency/European Group for Bone Marrow Transplantation report.
Fischer A; Friedrich W; Fasth A; Blanche S; Le Deist F; Girault D; Veber F; Vossen J; Lopez M; Griscelli C
Blood; 1991 Jan; 77(2):249-56. PubMed ID: 1985691
[TBL] [Abstract][Full Text] [Related]
4. [T-cell-depleted HLA non-identical bone marrow transplantation in the child: prevention of graft-versus-host reaction by administration of donor T lymphocytes alloreactive against the recipient].
Cavazzana-Calvo M; André-Schmutz I; Hacein-Bey S; Schindler J; Vitetta H; Dupuis S; Quartier P; Chedeville G; Vilmer E; Casanova JL; Buffet R; Caillat-Zucman S; Radford I; Le Deist F; Fischer A
J Soc Biol; 2001; 195(1):65-8. PubMed ID: 11530503
[TBL] [Abstract][Full Text] [Related]
5. In vivo infusion of anti LFA-1 antibody in HLA non-identical bone marrow transplantation in children: serum concentrations and biological effects.
Perez N; Le Deist F; Chatenoud L; Chanteloup N; Griscelli C; Fischer A
Bone Marrow Transplant; 1989 Jul; 4(4):379-84. PubMed ID: 2673457
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcomes of nonconditioned patients with severe combined immunodeficiency transplanted with HLA-identical or haploidentical bone marrow depleted of T cells with anti-CD6 mAb.
Patel NC; Chinen J; Rosenblatt HM; Hanson IC; Brown BS; Paul ME; Abramson SL; Ritz J; Shearer WT
J Allergy Clin Immunol; 2008 Dec; 122(6):1185-93. PubMed ID: 19084111
[TBL] [Abstract][Full Text] [Related]
7. Total lymphoid irradiation to prevent graft rejection in recipients of HLA non-identical T cell-depleted allogeneic marrow.
Soiffer RJ; Mauch P; Tarbell NJ; Anderson KC; Freedman AS; Rabinowe SN; Takvorian T; Murrey CI; Coral F; Bosserman L
Bone Marrow Transplant; 1991 Jan; 7(1):23-33. PubMed ID: 2043874
[TBL] [Abstract][Full Text] [Related]
8. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors.
Koehler M; Hurwitz CA; Krance RA; Coustan-Smith E; Williams LL; Santana V; Ribeiro RC; Brenner MK; Heslop HE
Bone Marrow Transplant; 1994 May; 13(5):571-5. PubMed ID: 7519937
[TBL] [Abstract][Full Text] [Related]
9. Similar survival following HLA-identical sibling transplantation for standard indication in children with haematologic malignancies: a single center comparison of mobilized peripheral blood stem cell with bone marrow transplantation.
Meisel R; Enczmann J; Balzer S; Bernbeck B; Kramm C; Schönberger S; Sinha K; Tröger A; Wernet P; Göbel U; Laws HJ; Dilloo D
Klin Padiatr; 2005; 217(3):135-41. PubMed ID: 15858704
[TBL] [Abstract][Full Text] [Related]
10. Bone marrow engraftment following unrelated donor transplantation utilizing busulfan and cyclophosphamide preparatory chemotherapy.
Klein JL; Avalos BR; Belt P; Taylor CA; Ezzone SA; Scholl MD; Fisher J; Young D; Copelan EA
Bone Marrow Transplant; 1996 Apr; 17(4):479-83. PubMed ID: 8722342
[TBL] [Abstract][Full Text] [Related]
11. Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion.
Keever-Taylor CA; Bredeson C; Loberiza FR; Casper JT; Lawton C; Rizzo D; Burns WH; Margolis DA; Vesole DH; Horowitz M; Zhang MJ; Juckett M; Drobyski WR
Biol Blood Marrow Transplant; 2001; 7(11):620-30. PubMed ID: 11760150
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic bone marrow transplantation: relation between chimaerism and immunity.
Vossen J
Verh K Acad Geneeskd Belg; 1998; 60(2):111-43; discussion 143-5. PubMed ID: 9703764
[TBL] [Abstract][Full Text] [Related]
13. Anti LFA1 monoclonal antibody for the prevention of graft rejection after T cell-depleted HLA-matched bone marrow transplantation for leukemia in adults.
Maraninchi D; Mawas C; Stoppa AM; Gaspard MH; Marit G; Van Ekthoven A; Reiffers J; Olive D; Hirn M; Delaage M
Bone Marrow Transplant; 1989 Mar; 4(2):147-50. PubMed ID: 2650783
[TBL] [Abstract][Full Text] [Related]
14. [Clinical study of a new protocol for acute graft-versus host disease prophylaxis in HLA-haploidentical bone marrow transplantation (BMT)].
Ji SQ; Chen HR; Wang HX; Yan HM; Liu J; Xue M; Zhu L
Zhonghua Xue Ye Xue Za Zhi; 2003 Aug; 24(8):416-9. PubMed ID: 14642179
[TBL] [Abstract][Full Text] [Related]
15. Prevention of bone marrow and cardiac graft rejection in an H-2 haplotype disparate mouse combination by an anti-LFA-1 antibody.
Cavazzana-Calvo M; Sarnacki S; Haddad E; De Coene C; Calise D; Yvon E; Cerf-Bensussan N; Fischer A
Transplantation; 1995 Jun; 59(11):1576-82. PubMed ID: 7778173
[TBL] [Abstract][Full Text] [Related]
16. Minimizing graft rejection in allogeneic T cell-depleted bone marrow transplantation.
Rigden JP; Cornetta K; Srour EF; Hanna M; Broun ER; Hromas R; Baute J; Hilton J; Cox E; Rubin L; Gonin R; Tricot G
Bone Marrow Transplant; 1996 Nov; 18(5):913-9. PubMed ID: 8932845
[TBL] [Abstract][Full Text] [Related]
17. In vitro analysis of donor bone marrow following monoclonal antibody treatment for the prevention of acute graft versus host disease.
Kohler PC; Erickson C; Finlay JL; Trigg ME; Edwards B; Hong R; Hank JA; Billing R; Bozdech M; Sondel PM
Cancer Res; 1986 Oct; 46(10):5413-8. PubMed ID: 3530439
[TBL] [Abstract][Full Text] [Related]
18. The role of thiotepa in allogeneic bone marrow transplantation for genetic diseases.
Rosales F; Peylan-Ramu N; Cividalli G; Varadi G; Or R; Naparstek E; Slavin S; Nagler A
Bone Marrow Transplant; 1999 May; 23(9):861-5. PubMed ID: 10338039
[TBL] [Abstract][Full Text] [Related]
19. Haploidentical peripheral blood and marrow stem cell transplantation in nine cases of primary immunodeficiency.
Lanfranchi A; Verardi R; Tettoni K; Neva A; Mazzolari E; Pennacchio M; Pasic S; Ugazio AG; Albertini A; Porta F
Haematologica; 2000 Nov; 85(11 Suppl):41-6. PubMed ID: 11268323
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic stem cell transplantation using myeloablative and reduced-intensity conditioning in patients with major histocompatibility complex class II deficiency.
Al-Mousa H; Al-Shammari Z; Al-Ghonaium A; Al-Dhekri H; Al-Muhsen S; Al-Saud B; Arnaout R; Al-Seraihy A; Al-Jefri A; Al-Ahmari A; Ayas M; El-Solh H
Biol Blood Marrow Transplant; 2010 Jun; 16(6):818-23. PubMed ID: 20079864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
